A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2018
At a glance
- Drugs Brivaracetam (Primary) ; Lorazepam
- Indications Epilepsy
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 09 May 2018 Status changed from recruiting to completed.
- 07 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Apr 2018.
- 07 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Apr 2018.